Biotech Values

[biocqr]

PLSE > Streetsweeper.... Shock Therapy Doesn't Cut It

http://www.thestreetsweeper.org/undersurveillance/Pulse_Biosciences__PLSE___Shock_Therapy_Doesn_t_Cut_It

The Burlingame, California biotech is working on shooting electrical pulses at cells in hopes of annihilating tumors. The stock recently shot up and is trading around record highs. We believe the stock action may have set up unwary stockholders for looming shockwaves. The amplified downside risks include:

*While institutional investors remain patently disinterested in Pulse, average investors appear to be following the lead of a billionaire investor.

*Average investors’ buying has fueled the $370 million market valuation.

*Now, though, average investors are getting bored with the billionaire. So the bottom could possibly drop out of Pulse quickly.

*Underwriter MDB Capital suddenly released 3.9 million shares that had been locked up since the IPO … making the stock available for sale a month early.

*Insiders recently sent out a sell signal by dumping all their stock in the lower $20s. Two weeks ago, two directors sold every single share they owned – a total of 50,000 shares.

*The company technology is unremarkable, unreliable and rather inferior to the competition. Unfortunately, even the major rival’s technology has not been readily adopted.

*Generously comparing Pulse technology to rival technology implies 92% downside for Pulse … or about $2 per share.